Stoke Therapeutics, Inc. Interest Expense
Stoke Therapeutics, Inc. (STOK) reported Interest Expense of $17.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2026-08-03
- Stoke Therapeutics, Inc. interest expense for the quarter ending 2026-06-30 was $17.00K, a 466.67% increase year-over-year.
- Stoke Therapeutics, Inc. interest expense for the quarter ending 2026-03-31 was $23.00K, a 2200.00% increase year-over-year.
- Stoke Therapeutics, Inc. interest expense for the quarter ending 2025-12-31 was $3.00K.
- Stoke Therapeutics, Inc. interest expense for the quarter ending 2025-09-30 was $3.00K.
- Stoke Therapeutics, Inc. interest expense for fiscal 2025 was $9.00K, a 65.38% decline from fiscal 2024.
- Stoke Therapeutics, Inc. interest expense for fiscal 2024 was $26.00K, a 46.94% decline from fiscal 2023.
- Stoke Therapeutics, Inc. interest expense for fiscal 2023 was $49.00K.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.00K 10-Q · filed 2026-08-03 | $41.00K 10-Q · filed 2026-08-03 | $43.00K derived: sum of 3 quarters · filed 2026-08-03 | $46.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $23.00K 10-Q · filed 2026-05-07 | $26.00K derived: sum of 2 quarters · filed 2026-05-07 | $29.00K derived: sum of 3 quarters · filed 2026-05-07 | $32.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $6.00K derived: sum of 2 quarters · filed 2026-03-16 | $9.00K derived: sum of 3 quarters · filed 2026-08-03 | $9.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $3.00K 10-Q · filed 2025-11-04 | $6.00K derived: sum of 2 quarters · filed 2026-08-03 | $6.00K 10-Q · filed 2025-11-04 | $6.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $3.00K 10-Q · filed 2026-08-03 | $3.00K 10-Q · filed 2026-08-03 | $3.00K derived: sum of 3 quarters · filed 2026-08-03 | $3.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $1.00K 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $5.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$1.00K derived: sum of 2 quarters · filed 2026-03-16 | $4.00K derived: sum of 3 quarters · filed 2026-03-16 | $26.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-04 | $5.00K derived: sum of 2 quarters · filed 2025-11-04 | $27.00K 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $5.00K 10-Q · filed 2025-08-12 | $27.00K 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $22.00K 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $49.00K 10-K · filed 2025-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |